C Of C-o- Group Is Nuclear C Of A Benzene Ring (e.g., Phenol, Phenolate, Etc.) Patents (Class 514/728)
  • Patent number: 9578892
    Abstract: Methods for preventing and treating disease include (i) providing to a person a nutrient material including at least one of lipid or carbohydrate, wherein protein constitutes less than 5 percent of the material's caloric content; (ii) instructing that, during a lower-protein time period of at least two days, the material be administered such that the person's intake of protein is less than 30 grams per day; (iii) instructing that nutrition be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 40 percent of the person's intake of calories during the lower-protein period; and (iv) instructing that, during a higher-protein time period of at least 24 hours following the lower-protein period, the person receives an average daily protein intake of at least 40 grams.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: February 28, 2017
    Inventor: James W. Hill
  • Patent number: 9226898
    Abstract: A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient, wherein the protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: January 5, 2016
    Inventor: Richard C. K. Yen
  • Patent number: 9205071
    Abstract: Arsenic compounds of general formula (I), their preparation methods, the pharmaceutical compositions containing the compounds, and their uses in the manufacture of medicaments for treating cancer, particularly leukemia, are disclosed.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: December 8, 2015
    Assignee: Changzhou Hi-Tech District Multiple Dimension Industry Technology Institute Co., Ltd.
    Inventors: Shuhua Gu, Xuecheng Wang
  • Patent number: 9029422
    Abstract: The present invention relates to a cosmetic method for treating and/or preventing greasy skin or greasiness-prone skin and/or the associated cutaneous aesthetic defects, comprising the topical application to the skin of a composition comprising, in a cosmetically acceptable medium, at least one compound of formula (I): in which: R represents a hydrogen atom or a saturated or unsaturated and linear or branched C1-C6 hydrocarbon radical; R? represents a saturated or unsaturated and linear or branched C1-C18 hydrocarbon radical, optionally substituted by a hydroxyl group; C—X represents C?O or CH—OH.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: May 12, 2015
    Assignee: L'Oreal
    Inventor: Maria Dalko
  • Publication number: 20150056160
    Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.
    Type: Application
    Filed: February 24, 2014
    Publication date: February 26, 2015
    Inventors: Nicholas Bachynsky, Woodie Roy
  • Patent number: 8961959
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: February 24, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Scott Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, James A. Shayman
  • Patent number: 8912234
    Abstract: The present invention is a method for obtaining a formulation of resveratrol and rice bran oil. The resulting product in the form of an oil or solid proves to increase the therapeutic potential of resveratrol by the synergistic action of the components of the rice oil. The product obtained through the method of the invention is an active principle which, when incorporated in nutraceutical and/or pharmaceutical compositions, provides antioxidant, anti-inflammatory, antiviral, cardioprotective, neuroprotective and/or cancer chemoprotective action, besides protecting against infections and ischemia, reducing obesity, and preventing illnesses of old age.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: December 16, 2014
    Assignee: UNIAO Brasileria de Educacao e Assistencia—Mantenedora da PUCRS
    Inventors: Andre Arigony Souto, Maria Martha Campos, Fernanda Bueno Morrone, Rodrigo Braccini Madeira da Silva, Izaque de Sousa Maciel
  • Patent number: 8802734
    Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula I: in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is —CH2O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is 1; and n is an integer of 1-5. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: August 12, 2014
    Assignee: Novaremed Limited
    Inventor: Eliahu Kaplan
  • Publication number: 20140178374
    Abstract: The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
    Type: Application
    Filed: August 17, 2012
    Publication date: June 26, 2014
    Applicants: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, EMORY UNIVERSITY
    Inventors: Xingming Deng, Jia Zhou, Chunyong Ding
  • Patent number: 8748468
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I:
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: June 10, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: David Loury, Tarak Mody
  • Patent number: 8722737
    Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: May 13, 2014
    Assignee: SCF Pharma Inc.
    Inventor: Samuel Fortin
  • Patent number: 8709454
    Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 29, 2014
    Assignee: L'Oreal
    Inventors: David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
  • Patent number: 8673983
    Abstract: The present invention provides an enzymatic and a chemical synthesis of melanins and novel melanins.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: March 18, 2014
    Assignee: Loyola University Chicago
    Inventors: Earle W. Holmes, Kenneth D. Thompson
  • Publication number: 20140018348
    Abstract: Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMPAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
    Type: Application
    Filed: July 7, 2013
    Publication date: January 16, 2014
    Inventor: Daniel C. Javitt
  • Publication number: 20130316985
    Abstract: A pharmaceutical composition including at least one compound of the Formulas (I), (II), or (III), or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, as defined herein. Also disclosed is a method of treatment of diseases which are pathophysiologically related to GPR35, the GPR35-hERG signaling complex, or both, as defined herein.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 28, 2013
    Applicant: Corning Incorporated
    Inventors: Huayun Deng, Ye Fang
  • Patent number: 8586633
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: November 19, 2013
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Patent number: 8574619
    Abstract: A method of reducing the cholesterol level of a subject by administering to that subject quercetin, vitamin C, vitamin B3, and statin.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: November 5, 2013
    Assignee: Quercegen Pharmaceuticals, LLC
    Inventor: Thomas Christian Lines
  • Patent number: 8552046
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: October 8, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: David Loury, Norbert Purro
  • Patent number: 8529928
    Abstract: Biodegradable polymers incorporating biomolecules and methods of their use are provided. Certain aspects provide biomolecules crosslinked with diglycidyl esters. The disclosed compositions have numerous applications including cellular regeneration, wound healing, and cellular differentiation.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: September 10, 2013
    Assignee: Georgia Tech Research Corporation
    Inventors: Yadong Wang, Blaine Zern, Christiane Gumera
  • Patent number: 8436083
    Abstract: A coating having an adhesive hydrophilic polymer and an amphiphilic additive. The amphiphilic additive has a hydrophilic chain, a biocidal functional group bonded to the hydrophilic chain, and a hydrophobic moiety bonded to the hydrophilic chain or to the biocidal functional group. A method of forming a biocidal surface by providing an article, and coating the article with the above coating. A compound having the formula: Y—(O—CH2—CH2)n—R—(CH2)m—CH3. Y is CH3 or H. R is X is a halogen, and m and n are independently selected positive integers.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: May 7, 2013
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: James H Wynne, Joanne M Jones-Meehan, Arthur W Snow, Leonard J Buckley
  • Patent number: 8415397
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: April 9, 2013
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Patent number: 8404714
    Abstract: The present invention provides combinations of dietary supplements and methods of using of these combinations to improve the health and production performance of animals. In particular, the combinations of the invention comprise antioxidants, trace minerals, organic acids, essential amino acids, and mixtures thereof.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: March 26, 2013
    Assignee: Novus International, Inc.
    Inventors: Mercedes Vazquez-Anon, Gavin Bowman, Steven Andrew Webb, James Richards, Robert Harrell, Junmei Zhao, Megharaja K. Manangi
  • Patent number: 8372890
    Abstract: Components that demonstrate an ?-glucosidase inhibitory activity and hyperglycemic inhibitory activity have clearly been provided from among the components included in Yacon. The present inventors found that as a result of screening for a strong anti-oxidant component in a Yacon aerial portion extract, an antioxidant activity was converged in a DIAION HP-20 column chromatography 50% methanol-eluted fraction of hot water extract. Thus, since a previously unidentified high-content component was confirmed, the present inventors conducted purification thereof, and thereby separated TCAA. As a result, this TCAA was found to be the component that demonstrates the ?-glucosidase inhibitory activity and hyperglycemic inhibitory activity.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: February 12, 2013
    Assignee: Zenyaku Kogyo Kabushikikaisha
    Inventors: Sumio Terada, Kikuo Itoh, Naoto Noguchi, Takashi Ishida
  • Patent number: 8367734
    Abstract: A stable suspension aerosol formulation of epinephrine is suitable for administration through inhalation comprising a therapeutically effective amount of epinephrine, hydrofluorocarbon propellant, co-solvent, surfactant, and antioxidant. The suspension aerosol formulation further comprises [pre-] pre-micronized epinephrine suspended in an alcohol/surfactant solution with hydrofluoroalkane propellant. The suspension formulation provides a highly efficient delivery of drug microparticles into the respirable region of patients' lungs and has the following advantages: lower dosage requirement, minimum alcohol content, with less impurities generated during storage, improved efficacy and safety, and exhibits no ozone depleting potential compared to a formulation containing chlorofluorocarbon.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: February 5, 2013
    Assignee: Amphastar Pharmaceuticals Inc.
    Inventors: Jianxin Gao, James Luo, Rong Zhou, Mary Ziping Luo, Jack Yongfeng Zhang
  • Patent number: 8367116
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: February 5, 2013
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. Macausland, Keith Baker
  • Patent number: 8349295
    Abstract: A method and apparatus for multicomponent surface modified aerosol particle production suitable for, for instance, therapeutic, cosmetic or diagnostic use in which an aerosol containing an active agent is introduced in an aerosol reactor together with a surface agent or surface agent source and/or precursor and wherein the surface agent and/or surface agent precursor is volatilizable. The surface agent vapor saturation ratio is elevated so to cause it to nucleate from the gas phase. Reactor conditions are maintaining such that the active agent remains in the condensed phase and provides a surface for the surface agent to deposit on the active agent containing aerosol particle thus producing surface modified aerosol particles. The method can be used for batch or continuous production. Particles made according to the method and powders and dispersions containing the particles are also described.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: January 8, 2013
    Assignee: Teicos Pharma Oy
    Inventors: David P. Brown, Esko I. Kauppinen, Anna Lahde, Janne Raula
  • Patent number: 8303991
    Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: November 6, 2012
    Assignee: Vectura Limited
    Inventors: John Staniforth, Matthew Michael James Green, David Alexander Vodden Morton
  • Patent number: 8246942
    Abstract: The invention relates to synergistic mixtures of o-phenylphenol with other microbicidally active compounds, such as bronopol (2-bromo-2-nitro-1,3-propanedial), 2-methyl-2H-isothiazol-3-one, 1,2-dibromo-2,4-dicyanobutane.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: August 21, 2012
    Assignee: LANXESS Deutschland GmbH
    Inventors: Peter Wachtler, Martin Kugler
  • Patent number: 8247457
    Abstract: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: August 21, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William E. Fahl, Arnold E. Ruoho, Minesh Mehta
  • Patent number: 8173707
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 8, 2012
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Patent number: 8173711
    Abstract: The present invention has its object to provide a safer and highly effective composition capable of relieving or preventing xerostomia. The present invention relates to an agent for relieving or preventing xerostomia comprising an oxidized coenzyme Q and/or a reduced coenzyme Q as active ingredients, a composition containing the agent for relieving or preventing xerostomia in a form of a food product, a health food, a dietary supplement, a supplement, an oral health care product, a medicament, a quasi drug, a pet food, a feed or the like, and a method for treating xerostomia and a method for reducing risks of xerostomia comprising administering the composition.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: May 8, 2012
    Assignees: Kaneka Corporation
    Inventors: Ichiro Saito, Kenji Fujii, Kazuya Hamada
  • Patent number: 8114914
    Abstract: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: February 14, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William E. Fahl, Arnold E. Ruoho, Minesh Mehta
  • Patent number: 8101213
    Abstract: The present invention provides compositions comprising an effective amount of xanthohumol and honokiol. The present invention comprises compositions comprising an effective amount of xanthohumol and genistein. The present invention comprises compositions comprising an effective amount of xanthohumol and guggulsterone. The compositions of the present invention may be effective to decrease mature adipocytes viability, induce apoptosis of mature adipocytes, increase lipolysis in mature adipocytes, and/or reduce adipogenesis during the maturation of pre-adipocytes. The present invention further provides methods of treating obesity, diabetes, osteoporosis or bone disorders in a subject, which comprise administering to the subject compositions comprising an effective amount of xanthohumol and honokiol, guggulsterone, or genistein.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: January 24, 2012
    Assignee: The University of Georgia Research Foundation, Inc
    Inventors: Clifton A. Baile, Mary Anne Della-Fera, Jeong-Yeh Yang, Srujana Rayalam, Hea Jin Park
  • Patent number: 8003704
    Abstract: Use is disclosed of (a) an AlDH-inhibitory amount of a Trp metabolite, or an analogue or derivative thereof or (b) a bioprecursor thereof, or (c) a potentiator of (a) and/or (b), in the preparation of a medicament for treating alcoholism and/or alcohol dependence.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: August 23, 2011
    Inventor: Abdulla Abu-Bakr Badawy
  • Patent number: 7947742
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: May 24, 2011
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Patent number: 7923032
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: April 12, 2011
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. MacAusland, Keith Baker
  • Publication number: 20110082176
    Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.
    Type: Application
    Filed: October 15, 2010
    Publication date: April 7, 2011
    Inventors: Norman C.W. Wong, Joseph E.L. Tucker, Henrik C. Hansen, Fabrizio S. Chiacchia, David McCaffrey
  • Publication number: 20110081431
    Abstract: The present invention relates to a composition comprising an NF?B-inhibitor and a non-retinoid collagen promoter.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 7, 2011
    Inventors: Simarna KAUR, Thierry ODDOS, Michael SOUTHALL, Samantha TUCKER-SAMARAS
  • Publication number: 20110053939
    Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning—X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 3, 2011
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Ewald M. AYDT, Remo Kranich
  • Patent number: 7875653
    Abstract: An emulsion comprising (a) more than about 40% by weight, based on the total weight of the lipid phase of the emulsion, of one or more polar and/or moderately polar lipids which exhibit an interfacial tension towards water of less than about 30 mN/m and (b) one or more 1,2-alkanediols having about 4 to about 8 carbon atoms and exhibiting a Ig pow of from about ?1 to about +3. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: January 25, 2011
    Assignee: Beiersdorf AG
    Inventors: Svea Behrens, Uta Meiring, Andreas Clausen, Andreas Bleckmann, Jens Nielsen
  • Patent number: 7846974
    Abstract: The compound represented by the general formula (I) is administered to a subject suffering from diabetes or obesity. In the formula (I), R1 and R2 independently represent an aliphatic hydrocarbon group having 1 to 10 carbon atoms or phenyl group, and arbitrary hydrogen atoms on the aliphatic hydrocarbon group and the phenyl group may be replaced by halogen, X1 represents halogen, and X2 represents hydrogen or halogen.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: December 7, 2010
    Assignee: National University Corporation Gunma University
    Inventors: Yuzuru Kubohara, Hiroshi Shibata
  • Patent number: 7750053
    Abstract: Products and compositions for preventing or reducing the severity of hypertension. These products contain (a) ferulic acid or a ferulate ester, and (b) caffeic acid and/or a chlorogenic acid. The preventive or remedy can suppress a rise in blood pressure and alleviate hypertension, and is usable as a food.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: July 6, 2010
    Assignee: KAO Corporation
    Inventors: Atsushi Suzuki, Ryuji Ochiai, Ichiro Tokimitsu
  • Patent number: 7700657
    Abstract: Novel vitamin D analogs, markedly active in the fields of cell proliferation and differentiation, are selected from among (4E,6E)-7-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl}-3-ethylnona-4,6-dien-3-ol, (E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, (3E,5E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)-phenyl]-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, (E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)ethyl]phenyl}-1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, and (3E,5E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, and the geometric isomers thereof and these compounds in which one or more of the hydroxyl functions are protected by a protective group —(C?O)—R, in which R is a linear or branched alkyl radical having from 1 to 6 carbon atoms, an aryl radical having from 6 to 10 carbon atoms, or an aralkyl radical having from 7 to 11 carbon atoms, the aryl radical or the aralkyl radical optional
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: April 20, 2010
    Assignee: Galderma Research & Development
    Inventor: Jean-Michel Bernardon
  • Publication number: 20100076018
    Abstract: The invention features compositions and methods that are useful for treating or preventing AAT deficiency and associated conditions. In addition, the invention provides methods for identifying compounds useful for treatment of AAT deficiency and associated conditions.
    Type: Application
    Filed: July 9, 2009
    Publication date: March 25, 2010
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Chen Liu, David A. Ostrov
  • Publication number: 20100056643
    Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.
    Type: Application
    Filed: November 5, 2009
    Publication date: March 4, 2010
    Inventors: Nicholas Bachynsky, Woodie Roy
  • Patent number: 7635722
    Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: December 22, 2009
    Assignee: Saint Jude Pharmaceuticals, Inc.
    Inventors: Nicholas Bachynsky, Woodie Roy
  • Publication number: 20080182872
    Abstract: The present invention provides a method of treating acute lung injuries, such as acute lung injury induced by peritonitis during sepsis, acute lung injury induced by intravenous bacteremia during sepsis, acute lung injury caused by smoke inhalation, acute lung injury occurring in a premature infant with deficiency of surfactant, acute lung injury caused by oxygen toxicity or acute lung injury caused by barotraumas from mechanical ventilation, using an ER? selective ligand such as 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol or 3-(3-fluoro-4-hydroxy-phenyl)-7-hydroxy-naphthalene-1-carbonitrile. The present invention further relates to use of ER? selective ligands or compositions thereof for the prevention of acute lung injuries in those being at risk thereof.
    Type: Application
    Filed: January 30, 2008
    Publication date: July 31, 2008
    Applicant: WYETH
    Inventors: James C. KEITH, George P. VLASUK
  • Patent number: 7169819
    Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: January 30, 2007
    Assignee: Childrens Hospital Los Angeles
    Inventors: Shanker Gupta, Barry J. Maurer, C. Patrick Reynolds, B. Rao Vishnuvajjala
  • Patent number: 7141605
    Abstract: A method of treating plant and animal systems and inanimate surfaces for the purposes of controlling plant pests, introducing pesticides and nutrients into plants, mitigating frost damage to plants, increasing crop yields, controlling certain plant diseases, controlling arthropod, bacterial, fungal, mycoplasma, rickettsia, and viral pests of animals and humans, and disinfecting inanimate surfaces. The method utilizes the unique multi-directional dispersion property of the tannate complex of picro ammonium formate and the tannate complex of picro cupric ammonium formate, in aqueous solution, combined with a minor amount of a surfactant sufficient to prevent formation of ammonium picrate, to penetrate plant and animal systems and inanimate surfaces and travelling multidirectionally therein. The method is carried out by introducing a small but effective amount of the tannate complex to the plant or animal system or inanimate surface.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: November 28, 2006
    Assignee: Phyton Corporation
    Inventor: Will H. Hartfeldt
  • Patent number: 7135600
    Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: November 14, 2006
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Diane Mary Coe, Stephen Barry Guntrip, Brian Edgar Looker, Panayiotis Alexandrou Procopiou